CohBar, Inc.
http://cohbar.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CohBar, Inc.
Deal Watch: Gurnet Point, Novo Holdings Buy Out Paratek
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
Hyloris On Track To Meet 2024 Target During Half-Year Update
Hyloris CEO Stijn Van Rompay said the firm is on track to meet its target of 30 portfolio products by 2024, delivering a confident Q2 half-year update despite some pushback from the US Food and Drug Administration on its Maxigesic IV compound.
Hyloris Raises €15m In Private Equity Offering
Value-added medicines firm Hyloris has raised €15m from new and existing investors through a private equity offering of nearly one million new shares.
Hyloris Outlines Ambitious Growth Strategy During Full-Year Results
Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice